Perspective Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
CATX$0.86+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares1 · Amount1 · Additional Paid-in Capital1 · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total | ||||||||||
| Balances at December 31, 2022 | 14,211,276 | $14 | $160,560 | $ | - | $(105,932) | $54,642 | |||
| Issuance of common stock in exchange for Viewpoint common stock, net | 13,654,507 | 14 | 54,539 | - | - | 54,553 | ||||
| Assumption of Viewpoint stock options and warrants at fair value | - | - | 7,836 | - | - | 7,836 | ||||
| Issuance of common stock pursuant to at-the-market offering, net | 123,883 | - | 364 | - | - | 364 | ||||
| Issuance of common stock pursuant to exercise of options | 191,319 | - | 554 | - | - | 554 | ||||
| Share-based compensation | - | - | 3,738 | - | - | 3,738 | ||||
| Net loss | - | - | - | - | (46,508) | (46,508) | ||||
| Balances at December 31, 2023 | 28,180,985 | $28 | $227,591 | $ | - | $(152,440) | $75,179 | |||
| Issuance of common stock pursuant to the Public Offering, net2 | 15,639,954 | 16 | 53,125 | - | - | 53,141 | ||||
| Issuance of Jan. 2024 Pre-funded Warrants, net2 | - | - | 10,208 | - | - | 10,208 | ||||
| Issuance of common stock pursuant to the Lantheus Investment Agreement, net2 | 5,634,235 | 6 | 20,840 | - | - | 20,846 | ||||
| Issuance of common stock pursuant to the March 2024 Investment Agreement, net2 | 9,200,998 | 9 | 82,010 | - | - | 82,019 | ||||
| Issuance of common stock pursuant to the ATM, net2 | 3,535,246 | 3 | 47,930 | - | - | 47,933 | ||||
| Issuance of common stock pursuant to the Registered Offering, net2 | 5,151,588 | 5 | 71,863 | - | - | 71,868 | ||||
| Issuance of May 2024 Pre-funded Warrants, net2 | - | - | 2,040 | - | - | 2,040 | ||||
| Cancellation of fractional shares due to the 1-for-10 reverse stock split | (114) | - | (1) | - | - | (1) | ||||
| Issuance of common stock pursuant to exercise of options | 304,795 | - | 1,253 | - | - | 1,253 | ||||
| Issuance of stock pursuant to exercise of common stock warrants | 22,786 | - | 125 | - | - | 125 | ||||
| Issuance of stock pursuant to exercise of Pre-funded Warrants | 3,000,991 | 3 | (3) | - | - | - | ||||
| Unrealized loss on available-for-sale securities | (51) | - | (51) | |||||||
| Share-based compensation | - | - | 5,387 | - | - | 5,387 | ||||
| Net loss | - | - | - | - | (79,279) | (79,279) | ||||
| Balances at December 31, 2024 | 70,671,464 | $70 | $522,368 | $(51) | $(231,719) | $290,668 | ||||
See Note 3, Investments and Agreements, for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.